Karen Carey

York

Managing Editor at BioWorld

Managing Editor at BioWorld MedTech

Analyst for Clarivate Analytics' BioWorld

Featured in: Favicon

bioworld.com Favicon

desmoinesregister.com Favicon

recordcourier.com Favicon

thehrdirector.com Favicon

minutehack.com Favicon

trainingindustry.com Favicon

trainingjournal.com Favicon

smartbrief.com Favicon

pmtoday.co.uk Favicon

corp.smartbrief.com

Articles

Spruce acquires Biomarin’s Sanfilippo drug, tralesinidase alfa

1 week ago | bioworld.com | Karen Carey

Spruce acquires Biomarin’s Sanfilippo drug, tralesinidase alfaAfter dropping development in December of its lead program, Spruce Biosciences Inc. has found new life by acquiring a BLA-ready enzyme replacement therapy for the rare genetic neurodegenerative disease Sanfilippo syndrome type B. If approved, the therapy, tralesinidase alfa, could bring Spruce a priority review voucher. BioWorld Clinical Deals and M&A Neurology/psychiatric Enzyme U.S.
Aiming for autoimmunity, Merida Bio launches with $121M series A

2 weeks ago | bioworld.com | Karen Carey

ImmuneAiming for autoimmunity, Merida Bio launches with $121M series AWhen an autoimmune disease disrupted the life of someone close to scientist Dario Gutierrez, an idea emerged for a new company called Merida Biosciences focused on removing misdirected antibodies and their negative effects using Fc biotherapeutics. BioWorld Science Financings Newco news Immune Protein Series A U.S.
Aiming for autoimmunity, Merida Bio launches with $121M series A

2 weeks ago | bioworld.com | Karen Carey

Home » Aiming for autoimmunity, Merida Bio launches with $121M series A BioWorld briefs for April 8, 2025. BioWorld MedTech briefs for April 7, 2025. The I148M mutation in the PNPLA3 gene, which encodes patatin-like phospholipase domain-containing protein 3, is known to confer risk of fatty liver, cirrhosis and... At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...
Airna’s $155M series B advances RNA editing drug AIR-001 for AATD

3 weeks ago | bioworld.com | Karen Carey

Genetic/congenitalAirna’s $155M series B advances RNA editing drug AIR-001 for AATDAs it prepares to advance its lead RNA editing candidate, AIR-001, into a phase I/II trial for alpha-1 antitrypsin deficiency, Airna Corp. Inc. closed an oversubscribed $155 million series B financing less than a year after completing its series A round.
Airna’s $155M series B advances RNA editing drug AIR-001 for AATD

3 weeks ago | bioworld.com | Karen Carey

Airna’s $155M series B advances RNA editing drug AIR-001 for AATDAs it prepares to advance its lead RNA editing candidate, AIR-001, into a phase I/II trial for alpha-1 antitrypsin deficiency, Airna Corp. Inc. closed an oversubscribed $155 million series B financing less than a year after completing its series A round. BioWorld Financings Gastrointestinal Respiratory Series B U.S.
Novo Nordisk licenses Lexicon’s preclinical obesity drug in $1B deal

3 weeks ago | bioworld.com | Karen Carey

Novo Nordisk licenses Lexicon’s preclinical obesity drug in $1B dealAs companies continually search for next-generation obesity prospects, one of the leaders in the disease space, Novo Nordisk A/S, has obtained an exclusive license to a preclinical-stage, first-in-class, small-molecule inhibitor of Acyl-CoA synthetase 5 (ACSL5) developed by Lexicon Pharmaceuticals Inc. BioWorld Deals and M&A Endocrine/metabolic Small molecule Europe U.S.
First Prader-Willi treatment Vykat XR FDA-approved: Soleno soars

4 weeks ago | bioworld.com | Karen Carey

First Prader-Willi treatment Vykat XR FDA-approved: Soleno soarsBecoming the first treatment for rare genetic disorder Prader-Willi syndrome, breakthrough therapy drug DCCR (diazoxide choline) gained U.S FDA approval as Vykat XR the evening before March 27, its PDUFA date, sending shares of developer Soleno Therapeutics Inc. up 34% in pre-market trading. BioWorld Regulatory U.S. Breakthrough therapy FDA
Mural Oncology sinks on nemvaleukin miss in ovarian cancer

1 month ago | bioworld.com | Karen Carey

Mural Oncology sinks on nemvaleukin miss in ovarian cancerLosing nearly 60% of its value, Mural Oncology plc backed away from its lead interleukin-2 (IL-2) drug, nemvaleukin alfa, in platinum-resistant ovarian cancer based on interim results showing it failed to reach significance in the overall survival primary endpoint. BioWorld Clinical Cancer Protein U.S.
CDC’s ACIP meeting rescheduled

1 month ago | bioworld.com | Karen Carey

CDC’s ACIP meeting rescheduledA meeting of the CDC’s Advisory Committee on Immunization Practices (ACIP) was rescheduled for April 15-16, according to the Federal Register. BioWorld Regulatory Infection Vaccine U.S. FDA
Elevation buries claudin 18.2 ADC for cancer, slashes staff by 70%

1 month ago | bioworld.com | Karen Carey

Elevation buries claudin 18.2 ADC for cancer, slashes staff by 70% Elevation Oncology Inc. has nixed its lead pipeline product, a claudin 18.2 antibody-drug conjugate (ADC) called EO-3021, on disappointing phase I data, sending shares tumbling by 42% and placing its preclinical HER3 ADC to the forefront of development. BioWorld Clinical Cancer Antibody-drug conjugate U.S.